The US Oncology Network | Strategic Alliance Partners

Latest from The US Oncology Network


The Future of Reimbursement: How AI Can Revolutionize Oncology Practices

May 15, 2023

By retrospectively analyzing health care financial data and using the intelligence generated to guide future claims to a more successful outcome, machine learning platforms may reduce the need for repeated insurance submissions and appeals and can improve the practice’s clean claim rate.

Dr Coleman on Response Rates With Mirvetuximab Soravtansine in Ovarian Cancer

March 27, 2023

Robert L. Coleman, MD, FACOG, FACS, discusses an analysis of the phase 3 SORAYA trial evaluating response rates in patients with platinum-resistant ovarian cancer who received mirvetuximab soravtansine at different points in their disease course.

Building the Optimal Patient Experience Takes Planning and Effort

November 22, 2022

Ensuring a positive patient experience should be a top priority throughout the entire treatment journey, as higher patient satisfaction can drive improved health outcomes, treatment adherence, and quality of life.

Acalabrutinib With or Without Obinutuzumab Maintains Long-Term Survival Benefit in Untreated CLL

August 24, 2022

Jeff P. Sharman, MD, discusses the meaning of the long-term follow-up data from ELEVATE-TN, the efficacy of acalabrutinib regimens in patients with treatment-naïve chronic lymphocytic leukemia with deletion 17p or TP53 mutations, and factors to consider when adding obinutuzumab to acalabrutinib.

Rucaparib Maintenance Shows PFS Benefit in Ovarian Cancer, Independent of HRD Status

June 06, 2022

Rucaparib elicited a significant improvement in progression-free survival outcomes vs placebo as first-line maintenance therapy in patients with ovarian cancer who responded to first-line platinum-based chemotherapy across patient subgroups.

Long-Term Follow-Up Supports Acalabrutinib-Based Regimens in Treatment-Naïve CLL

June 04, 2022

At approximately 5 years of follow-up, findings from the phase 3 ELEVATE-TN study show that treatment outcomes are more favorable with acalabrutinib with or without obinutuzumab compared with obinutuzumab and chlorambucil in treatment-naïve chronic lymphocytic leukemia.

A Widening Scope of Treatment Options Advances Care in Bladder Cancer and RCC

May 18, 2022

Mark T. Fleming, MD, reviews the use of first-line checkpoint inhibitors in bladder cancer, the efficacy of enfortumab vedotin-ejfv in urothelial cancer, and the clinical benefits of using different mechanisms of action to treat renal cell carcinoma.

Patients With HER2+ Breast Cancer Who Achieve pCR With Neoadjuvant HER2-Targeted Therapy Have Better DFS, OS

February 09, 2022

Patients with HER2-positive, early-stage breast cancer who achieved a pathologic complete response after receiving HER2-targeted therapy experienced better outcomes in terms of disease-free survival and overall survival vs those who did not, according to data from a real-world study.